Piramal Pharma is three businesses wearing one name. It makes drugs to order for other pharmaceutical companies — ₹4,915 crore last year, 55% of revenue, from fifteen sites in India, Britain and America. It sells hospital drugs of its own, mainly anaesthetics and pain products, where it is the largest supplier of sevoflurane in the United States with 48% of that market — ₹2,703 crore, 30%. And it sells consumer brands in India such as Lacto Calamine and Little's — ₹1,274 crore, 14%. It is demonstrably good at the hard part: 38 regulatory inspections last year, three of them by the American FDA, produced no adverse classification. It is not yet good at the part that reaches shareholders — ₹13,837 crore of capital earned 1.2%.
For a contract manufacturer the measures that matter are whether customers come back and whether regulators stay away. Piramal reads well on both. Its net promoter score is 60 on a scale running from minus 100 to plus 100, where a third-party benchmark found the average contract manufacturer scores below zero. It carries 157 molecules across development stages, about 25 of them late-stage, where roughly half typically reach the market. Last year it passed 38 regulatory inspections with no adverse classification and 209 customer audits — its highest ever in a single year — with no critical observations. Customers inspect a contract manufacturer far more often than regulators do, and that second number is the one a rival would find hardest to match.
More than is comfortable. Borrowings rose from ₹4,856 crore to ₹5,675 crore last year, leaving ₹4,451 crore of net debt against ₹8,163 crore of net worth. The ratio of 0.70 sounds unremarkable until the debt is set against earnings rather than assets: it is about five times last year's operating profit of ₹922 crore. The June quarter shows the arithmetic plainly — ₹285 crore of operating profit, then ₹88 crore of interest and ₹224 crore of depreciation, and the quarter ends in a loss. What keeps this manageable rather than dangerous is cash: ₹1,653 crore came in from operations last year.
Piramal Pharma went backwards last year and is growing sharply now. Revenue fell 3% in the year to March 2026, to ₹8,869 crore, and the company lost ₹326 crore. In the June quarter revenue rose 17% to ₹2,270 crore, operating profit rose 72% to ₹285 crore, and the margin went from 8.5% to 12.5%. Profit has not caught up — the quarter was still a ₹69 crore loss. One caution the company volunteered on its own earnings call, which is easy to miss: roughly 9 to 10 percentage points of that 17% came from a weaker rupee rather than from selling more.
Sales have compounded 7% a year over five years, from ₹6,315 crore to ₹8,869 crore — slow for an industry growing in the low teens. Profit has not compounded at all. The six years read ₹835 crore, ₹376 crore, a ₹186 crore loss, ₹18 crore, ₹91 crore, and a ₹326 crore loss. Five years of added sales have produced no added profit, which is the single most important sentence on this page.
Almost entirely on its own. The one purchase last year was a single brand — Kenalog, bought from Bristol Myers Squibb — which needed no factory and no sales force because it slots into a network already reaching 6,000 hospitals. Everything else is building: $90 million committed to two American sites for sterile injectables and antibody-drug-conjugate work, and $120–135 million of capital spending guided for this year against $21 million spent in the first quarter. Building is the slower way to grow, and part of why returns look poor while it is under way.
Worsening over five years, improving over one quarter. The operating margin was 22.6% in FY21 and 10.4% last year, with everything in between falling between 9% and 16%. The June quarter came in at 12.5% against 8.5% a year earlier. For scale, Divi's earns 32.6% and Anthem 39.3% on the same measure. Management's explanation does not change from call to call: the overseas plants run below the scale they were built for, and margin follows utilisation. Its stated target is 25% by FY30, which means more than doubling from here.
This is the weakest number on the page. Piramal Pharma employs ₹13,837 crore of capital and earned 1.2% on it last year. The five-year record — 7.0%, 1.9%, 5.0%, 6.5%, 1.2% — shows the bad year is not an aberration. Laurus earns 18.0% on its capital, Divi's 21.5% and Anthem 29.6%. A business earning less on its capital than it pays on its borrowings is not yet paying its own way, and that, rather than any single quarter, is what the recovery has to fix.
Cash is the one thing this company does not lack. It generated ₹1,653 crore from operations last year while reporting a ₹326 crore loss — the gap is depreciation on plants paid for years ago, which costs the accounts but not the bank balance. Customers pay in 89 days, a little faster than the 94 of a year before. Stock is the problem: inventory has gone from 92 days to 126, tying up ₹3,064 crore, which is more than the company's entire consumer business turns over in two years.
Piramal Pharma is run by Nandini Piramal as executive chairperson and Peter DeYoung, also a member of the promoter group, as chief executive of the global pharma business, with Vivek Valsaraj as finance director — three of the ten board seats, on a board with six independent directors. The promoter group holds 34.80%, none of it pledged. Two things sit uneasily against that. The auditors are Suresh Surana & Associates, a mid-tier firm, for a group with twenty overseas subsidiaries. And pay to directors and key management rose 64% to ₹25.87 crore in a year the company lost ₹326 crore.
Nothing in the accounts and nothing on the record. The auditors signed off with no qualification and nothing they wanted to draw attention to, and disputed claims total about ₹95 crore, mostly a ₹78 crore indirect-tax matter — small against ₹8,869 crore of revenue. The regulatory record is genuinely clean: 38 inspections last year with no adverse classification. One footnote is worth knowing rather than worrying about. An associate, Yapan Bio, could not supply audited accounts to March, so nine months of unaudited figures were used in the group's numbers instead.
What makes Piramal Pharma different is that it is not one company. A customer can have a molecule developed in Ahmedabad, made at scale in Michigan and filled into sterile vials in Kentucky — what the company calls its East-West network, across fifteen contract-manufacturing sites on three continents, and something no Indian rival offers at the same scale. Two-thirds of revenue comes from the regulated markets of America, Europe and Japan. That same breadth is why the accounts read poorly: three businesses and twenty subsidiaries, several still running below the scale they were built for.
In contract manufacturing: Divi's Laboratories, Syngene, Cohance and Sai Life at home, and Lonza, Catalent and Samsung Biologics abroad. Piramal is mid-sized among them and, unusually for an Indian company, competes inside America with American plants. In hospital drugs the field is different again — it holds 48% of the American sevoflurane market, where its competition is increasingly Chinese. Asked directly in July whether that pressure had passed, management said the Chinese competitive situation "remains", though its own response had begun to bear fruit.
Helping: American biotech funding has recovered, which is lifting enquiries across the network; customers want manufacturing that is not in China; and the newly bought Kenalog brand starts contributing from the September quarter. Hurting: one large customer has been working through excess stock of an on-patent product and management expects no orders from it this year; Chinese competition in anaesthetics outside America; and overseas plants still short of the scale that would make them profitable. The odd one out is the rupee, which flattered last quarter's growth by 9 to 10 percentage points and can reverse just as quietly.
Three businesses, three different cycles, and only one of them is the contract manufacturing story. That half — 55% of revenue, from fifteen sites in India, Britain and America — moves with customers' research spending, which is why Piramal's first half last year went soft and why this year's recovery has the same cause running the other way. The hospital drugs business, 30% of revenue, follows nothing of the sort: it turns on holding 48% of the American sevoflurane market against Chinese competition that management said in July remains. The consumer brands follow Indian shelves. Averaging three cycles into one outlook is what makes this company hard to read, because a good year in one can hide a bad year in another.
At ₹209.55 on 7 August 2026 Piramal Pharma cost 3.1 times its sales where Divi's cost 20.8 and Anthem 22.2 — and unlike either, it lost money last year. Those are the same fact: Divi's turns a third of its revenue into operating profit and Piramal turns a tenth. That price was its twelve-month high, so the recovery that began in the June quarter was already being paid for. What is left to buy is the distance between a 10.4% margin today and the 25% the company has told investors it is targeting by FY30 — cheap if it gets there, dear if it does not.
There is no price-to-earnings ratio, because there are no earnings for it to divide. On the measures that still work the share was far cheaper than its peers: at ₹209.55 on 7 August 2026, 3.1 times sales and 3.4 times book value, against 20.8 and 13.1 for Divi's, 22.2 and 15.5 for Anthem, 14.6 and 18.8 for Laurus. That gap is not an oversight by the market. Those three earn between 18% and 30% on their capital; Piramal earns 1.2%. You pay little for each rupee of its sales precisely because so little of that rupee survives the journey to the bottom of the page.
The chart shows foreign institutions falling from 30.18% to 12.52% in a single quarter. They did not sell. In the June filing the company moved Carlyle's 17.93%, held through CA Alchemy Investments, out of foreign direct investment and into foreign companies — the first counts as institutional, the second does not. The same shares, one box to the left. Underneath it the register barely moved: promoters 34.80% against 34.86%, Indian funds 14.57% against 15.61%, and 461,096 shareholders against 450,661 three months earlier. Every figure here follows the filing as submitted, which is why the cliff is drawn rather than smoothed.
Yes, and one of them matters more than the rest. Carlyle, the American private equity firm, holds 17.93% through CA Alchemy Investments, making it the largest shareholder after the promoter trust and larger than any single promoter entity. HDFC Flexi Cap Fund holds 7.68%, an unusually concentrated position for one scheme in one company. East Bridge Capital Master Fund holds 2.0% and Indiahold 1.3%. No other holder is above 1%.
No dividend for last year, after ₹0.11 a share in FY24 and ₹0.14 in FY25 — token payments, now stopped, which is the honest response to a loss. No buyback either. Money has been moving the other way: borrowings rose ₹818 crore last year, and before that the company raised ₹3,977 crore of equity in FY21 and ₹818 crore in FY23. Employee share options added 0.26% to the share count last year, which is small enough to ignore.
Loading…